Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California
Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California.
Drug Metab Dispos. 2021 Apr;49(4):330-336. doi: 10.1124/dmd.120.000337. Epub 2021 Feb 2.
Volume of distribution (V) is a primary pharmacokinetic parameter used to calculate the half-life and plasma concentration-time profile of drugs. Numerous models have been relatively successful in predicting V, but the model developed by Korzekwa and Nagar is of particular interest because it utilizes plasma protein binding and microsomal binding data, both of which are readily available in vitro parameters. Here, Korzekwa and Nagar's model was validated and expanded upon using external and internal data sets. Tissue binding, plasma protein binding, V, physiochemical, and physiologic data sets were procured from literature and Genentech's internal data base. First, we investigated the hypothesis that tissue binding is primarily governed by passive processes that depend on the lipid composition of the tissue type. The fraction unbound in tissues (fu) was very similar across human, rat, and mouse. In addition, we showed that dilution factors could be generated from nonlinear regression so that one fu value could be used to estimate another one regardless of species. More importantly, results suggested that microsomes could serve as a surrogate for tissue binding. We applied the parameters from Korzekwa and Nagar's V model to two distinct liver microsomal data sets and found remarkably close statistical results. Brain and lung data sets also accurately predicted V, further validating the model. V prediction accuracy for compounds with log D > 1 significantly outperformed that of more hydrophilic compounds. Finally, human V predictions from Korzekwa and Nagar's model appear to be as accurate as rat allometry and slightly less accurate than dog and cynomolgus allometry. SIGNIFICANCE STATEMENT: This study shows that tissue binding is comparable across five species and can be interconverted with a dilution factor. In addition, we applied internal and external data sets to the volume of distribution model developed by Korzekwa and Nagar and found comparable V prediction accuracy between the V model and single-species allometry. These findings could potentially accelerate the drug research and development process by reducing the amount of resources associated with in vitro binding and animal experiments.
分布容积(V)是用于计算药物半衰期和血浆浓度-时间曲线的主要药代动力学参数。许多模型在预测 V 方面都取得了相对成功,但 Korzekwa 和 Nagar 开发的模型特别有趣,因为它利用了血浆蛋白结合和微粒体结合数据,这两种数据都是体外易于获得的参数。在这里,Korzekwa 和 Nagar 的模型使用外部和内部数据集进行了验证和扩展。组织结合、血浆蛋白结合、V、物理化学和生理数据集从文献和 Genentech 的内部数据库中获得。首先,我们调查了组织结合主要由依赖组织类型脂质组成的被动过程控制的假设。组织中的未结合分数(fu)在人和大鼠、小鼠中非常相似。此外,我们表明可以从非线性回归生成稀释因子,以便无论物种如何,都可以使用一个 fu 值来估计另一个值。更重要的是,结果表明微粒体可以作为组织结合的替代物。我们将 Korzekwa 和 Nagar 的 V 模型的参数应用于两个不同的肝微粒体数据集,发现结果非常接近统计学结果。脑和肺数据集也准确预测了 V,进一步验证了该模型。对于 log D > 1 的化合物,V 的预测准确性明显优于更亲水的化合物。最后,Korzekwa 和 Nagar 的模型对人的 V 预测似乎与大鼠的比例预测一样准确,略低于狗和食蟹猴的比例预测。意义:本研究表明,五种物种的组织结合具有可比性,可以通过稀释因子相互转换。此外,我们将内部和外部数据集应用于 Korzekwa 和 Nagar 开发的体积分布模型,并发现 V 模型和单物种比例预测之间具有可比的 V 预测准确性。这些发现有可能通过减少与体外结合和动物实验相关的资源量,加速药物研发过程。